Superiority of amino-modified chiral mesoporous silica nanoparticles in delivering indometacin
Source abstract
Abstract
The present study established indometacin (IMC) delivery system with chiral mesoporous silica nanoparticles (CMSNs) and amino-modified chiral mesoporous silica nanoparticles (Amino-CMSNs) that previously reported as pharmaceutical excipients, and their systemic biological effects, mainly consisting of in vitro drug intestinal permeability, haemolysis assay, in vivo pharmacokinetics, anti-inflammation pharmacodynamics and gastric irritation, were addressed. It turned out that the two IMC delivery systems established by CMSN and Amino-CMSN significantly improved drug intestinal permeability due to the improved drug dissolution caused by conversion of drug crystalline state to amorphous phase. Further, IMC-loaded Amino-CMSN was the superior choice because of its higher dissolution rate. Furthermore, CMSN and Amino-CMSN were safe to be circulated in blood, and Amino-CMSN with significant lower haemolysis ratio than CMSN was better for the minimum haemolytic behaviour. Oral bioavailability and anti-inflammation effect of IMC delivery systems established by CMSN and Amino-CMSN were enhanced compared with IMC, which was attributed to the primary cause of the improvement of IMC dissolution, and Amino-CMSN exhibited better biological effect. As a result of these facts, it is believed that the effective delivery of IMC by Amino-CMSN will provide a new candidate to formulate poorly soluble drugs so as to significantly develop pharmaceutical application.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Mesoporous Materials and Catalysis · Analytical Chemistry and Chromatography · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Wuya College of Innovation, Shenyang Pharmaceutical University
School of Pharmacy, Shenyang Pharmaceutical University
College of basic medical sciences, Shenyang medical college
References (49)
Show source-provided references
1. 10.1016/j.colsurfb.2013.04.00910.1016/j.colsurfb.2013.04.009 ↗
2. 10.1016/j.colsurfb.2016.02.00910.1016/j.colsurfb.2016.02.009 ↗
3. 10.1016/j.msec.2015.05.03910.1016/j.msec.2015.05.039 ↗
4. 10.1016/j.msec.2015.09.09110.1016/j.msec.2015.09.091 ↗
5. 10.1002/adma.20110476310.1002/adma.201104763 ↗
6. 10.1016/j.addr.2012.07.01810.1016/j.addr.2012.07.018 ↗
7. 10.1039/c0jm03851b10.1039/c0jm03851b ↗
8. 10.1080/21691401.2017.129064810.1080/21691401.2017.1290648 ↗
9. 10.1039/C2CS35297D10.1039/C2CS35297D ↗
10. 10.1038/nature0252910.1038/nature02529 ↗
11. 10.1016/j.materresbull.2014.11.03010.1016/j.materresbull.2014.11.030 ↗
12. 10.1021/cm06110710.1021/cm061107 ↗
13. 10.1002/adma.20060270310.1002/adma.200602703 ↗
14. 10.1002/adfm.20080063110.1002/adfm.200800631 ↗
15. 10.1039/C0CS00002G10.1039/C0CS00002G ↗
16. 10.1002/chem.20110214610.1002/chem.201102146 ↗
17. 10.1016/j.addr.2008.03.01210.1016/j.addr.2008.03.012 ↗
18. 10.1039/a704156j10.1039/a704156j ↗
19. 10.1002/adfm.20040062210.1002/adfm.200400622 ↗
20. 10.1002/adma.20030632310.1002/adma.200306323 ↗
21. 10.1021/ja026855o10.1021/ja026855o ↗
22. 10.1016/j.ejpb.2007.05.01010.1016/j.ejpb.2007.05.010 ↗
23. 10.1016/j.addr.2007.05.01410.1016/j.addr.2007.05.014 ↗
24. TanejaShilpi S, Khatri SK. Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement. Artif Cell Nanomed Biotechnol. 2016;44:978–984.
25. 10.3109/21691401.2015.101226110.3109/21691401.2015.1012261 ↗
26. 10.1016/j.ejpb.2005.05.00910.1016/j.ejpb.2005.05.009 ↗
27. 10.1016/S0169-409X(00)00118-610.1016/S0169-409X(00)00118-6 ↗
28. 10.3109/10731199.2010.51625910.3109/10731199.2010.516259 ↗
29. 10.1080/21691401.2016.118572610.1080/21691401.2016.1185726 ↗
30. 10.1016/j.addr.2007.05.00310.1016/j.addr.2007.05.003 ↗
31. 10.1016/j.jcis.2011.07.02210.1016/j.jcis.2011.07.022 ↗
32. 10.1016/j.ejpb.2011.07.00110.1016/j.ejpb.2011.07.001 ↗
33. 10.1016/j.micromeso.2011.06.00110.1016/j.micromeso.2011.06.001 ↗
34. 10.1016/j.ijpharm.2015.07.01410.1016/j.ijpharm.2015.07.014 ↗
35. 10.1016/j.micromeso.2012.12.03710.1016/j.micromeso.2012.12.037 ↗
36. 10.1016/j.msec.2013.08.01410.1016/j.msec.2013.08.014 ↗
37. 10.1016/j.ijpharm.2012.09.00810.1016/j.ijpharm.2012.09.008 ↗
38. 10.3109/02713683.2010.53629410.3109/02713683.2010.536294 ↗
39. 10.3109/0265204090324344510.3109/02652040903243445 ↗
40. 10.1021/acs.molpharmaceut.6b0102310.1021/acs.molpharmaceut.6b01023 ↗
41. 10.1021/acs.molpharmaceut.6b0080310.1021/acs.molpharmaceut.6b00803 ↗
42. 10.1021/acs.molpharmaceut.5b0029910.1021/acs.molpharmaceut.5b00299 ↗
43. 10.1021/acs.molpharmaceut.5b0085310.1021/acs.molpharmaceut.5b00853 ↗
44. 10.1080/21691401.2016.127692410.1080/21691401.2016.1276924 ↗
45. 10.1080/21691401.2016.120226210.1080/21691401.2016.1202262 ↗
46. 10.1016/S0142-9612(99)00148-910.1016/S0142-9612(99)00148-9 ↗
47. 10.1021/ja064594310.1021/ja0645943 ↗
48. 10.1016/j.ejps.2015.02.00810.1016/j.ejps.2015.02.008 ↗
49. 10.1016/j.ejpb.2011.12.00210.1016/j.ejpb.2011.12.002 ↗